Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems

Definitions

• the present invention is directed to novel multicylic compounds and the use thereof. More particularly, the present invention relates to novel multicyclic compounds and their use, for example, for the inhibition of protein kinase activity.
• Protein kinases play a critical role in the control of cell growth and differentiation.
• Protein kinases Aberrant expression or mutations in protein kinases have been shown to lead to uncontrolled cell proliferation, such as malignant tumour growth, and various defects in developmental processes, including cell migration and invasion, and angiogenesis. Protein kinases are therefore critical to the control, regulation, and modulation of cell proliferation in diseases and disorders associated with abnormal cell proliferation. Protein kinases have also been implicated as targets in central nervous system disorders such as Alzheimer's disease, inflammatory disorders such as psoriasis, bone diseases such as osteoporosis, atheroscleroses, restenosis, thrombosis, metabolic disorders such as diabetes, and infectious diseases such as viral and fungal infections.
• One of the most commonly studied pathways involving kinase regulation is cellular signaling from receptors at the cell surface to the nucleus.
• each receptor is determined by its pattern of expression, ligand availability, and the array of downstream signal transduction pathways that are activated by a particular receptor.
• This pathway includes a cascade of kinases in which members of the Growth Factor receptor Tyrosine Kinases deliver signals via phosphorylation to other kinases such as Src Tyrosine kinase, and the Raf, Mek and Erk serine/threonine kinase families.
• Src Tyrosine kinase the Growth Factor receptor Tyrosine Kinases
• Raf Raf, Mek and Erk serine/threonine kinase families.
• Each of these kinases is represented by several family members which play related, but functionally distinct roles.
• the loss of regulation of the growth factor signaling pathway is a frequent occurrence in cancer as well as other disease states. Fearon, Genetic Lesions in Human Cancer, Molecular Oncology, 1996, 143-178.
• VEGF vascular endothelial growth factor
• VEGFR tyrosine kinases Suppression of formation of new blood vessels by inhibition of the VEGFR tyrosine kinases would have utility in a variety of diseases, including treatment of solid tumors, diabetic retinopathy and other intraocular neovascular syndromes, macular degeneration, rheumatoid arthritis, psoriasis, and endometriosis.
• CDKs cyclin dependent kinases
• Inhibitors of kinases involved in mediating or maintaining particular disease states represent novel therapies for these disorders.
• Examples of such kinases include inhibition of Src, raf, and the cyclin-dependent kinases (CDK) 1 , 2, and 4 in cancer, CDK2 or
• PDGF-R kinase in restenosis CDK5 and GSK3 kinases in Alzheimers, c-Src kinase in osteoporosis, GSK-3 kinase in type-2 diabetes, p38 kinase in inflammation, VEGF-R 1-3 and TIE-I and -2 kinases in angiogenesis, UL97 kinase in viral infections, CSF-IR kinase in bone and hematopoietic diseases, and Lck kinase in autoimmune diseases and transplant rejection.
• SAPK stress-activated protein kinase pathway
• INKs c-jun N-terminal kinases
• the JNKs are mitogen-activated protein kinases (MAPKs) that are encoded by three distinct genes, jnkl ,jnk2 an ⁇ jnk3, which can be alternatively spliced to yield a variety of different JNK isoforms (Gupta et al., EMBO J 1996, 15, 2760).
• the isoforms differ in their ability to interact with and phosphorylate their target substrates.
• Activation of JNK is performed by two MAPK kinases (MAPKK), MKK4 and MKK7.
• MKK4 is an activator of JNK as well as an additional MAPK, p38, while MKK7 is a selective activator of JNK.
• MLK4 and MKK7 A number of MAPKK kinases are responsible for activation of MKK4 and MKK7, including the MEKK family and the mixed lineage kinase, or MLK family.
• the MLK family is comprised of six members, including MLKl, MLK2, MLK3, MLK6, dual leucine zipper kinase (DLK) and leucine zipper-bearing kinase (LZK).
• DLK dual leucine zipper kinase
• LZK leucine zipper-bearing kinase
• MLK2 is also known as MST Katoh, et al. Oncogene, 1994, 10, 1447).
• kinases are proposed to be upstream of the MAPKKKs, including but not restricted to germinal center kinase (GCK), hematopoietic progenitor kinase (HPK), and Rac/cdc42.
• GCK germinal center kinase
• HPK hematopoietic progenitor kinase
• Rac/cdc42 Rac/cdc42.
• Specificity within the pathway is contributed, at least in part, by scaffolding proteins that bind selected members of the cascade.
• the INK interacting protein- 1 (JIP-I) binds HPKl, DLK or MLK3, MKK7 and JNK, resulting in a module which enhances JNK activation (Dickens et al. Science 1997, 277, 693).
• Manipulation of the activity of the SAPK pathway can have a wide range of effects, including promotion of both cell death and cell survival in response to various pro- apoptotic stimuli.
• down-regulation of the pathway by genetic disruption of the gene encoding JNK3 in the mouse provided protection against kainic acid-induced seizures and prevented apoptosis of hippocampal neurons (Yang et al. Nature 1997, 389, 865).
• inhibitors of the INK pathway such as JIP-I inhibit apoptosis (Dickens, supra).
• the activity of the JNK pathway appears to be protective in some instances.
• Thymocytes in which MKK4 has been deleted display increased sensitivity to CD95- and CD3 mediated apoptosis (Nishina et al. Nature 1997, 385, 350).
• Overexpression of MLK3 leads to transformation of NIH 3T3 fibroblasts (Hartkamp et al. Cancer Res. 1999, 59, 2195).
• An area the present invention is directed toward is identification of compounds that modulate the MLK members of the SAPK pathway and promote either cell death or cell survival.
• Inhibitors of MLK family members would be anticipated to lead to cell survival and demonstrate therapeutic activity in a variety of diseases, including chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease and acute neurological conditions such as cerebral ischemia, traumatic brain injury and spinal injury.
• Inhibitors of MLK members leading to inhibition of the SAPK pathway (JNK activity) would also display activity in inflammatory diseases and cancer.
• one object of the present invention is to provide novel fused
• [d]pyridazin-7-ones which are kinase inhibitors.
• the compounds of the present invention are inhibitors of one or more of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK).
• VEGFR vascular endothelial growth factor receptor
• MLK mixed lineage kinase
• CDK cyclin-dependent kinase
• It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention, or a pharmaceutically acceptable salt form thereof.
• the disorders are characterized by the aberrant activity of one or more of the vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK), and the method comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of at least one of the compounds of the present invention.
• VEGFR vascular endothelial growth factor receptor
• MLK mixed lineage kinase
• CDK cyclin-dependent kinase
• the present invention provides a novel compound of Formula (I):
• ring B together with the carbon atoms to which it is attached, is a phenylene ring, wherein 1 or 2 carbon atoms of the phenylene ring are optionally replaced by nitrogen atoms ;
• R 1 and R 2 are independently selected from:
• R 1 and R 2 together form a methylenedioxy or an ethylenedioxy group
• R 3 and R 4 are independently selected from hydrogen, halogen, C 1 -C 4 alkyl, and -O(CR a 2 ) n R 8 ; alternatively, R 2 and R 3 together form a methylenedioxy or an ethylenedioxy group
• R 5 is selected from Ce-C 12 aryl substituted with 0 to 3 R 9 groups
• R 6 is selected from hydrogen, — CH2N(R d )(R e ), and the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
• R 7 is selected from hydrogen, Ci -Ce alkyl substituted with 0 to 3 R 10 groups, C 2 -Ce alkenyl substituted with 0 to 3 R 10 groups,
• R 8 is selected from hydrogen, C1-C4 alkyl, C 2 -C 4 alkenyl, C 2 -C4 alkynyl,
• R 9 is selected from:
• Ci-C 6 alkyl C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -C] 2 aryl, C 3 -C 7 cycloalkyl, C5-C10 heterocyclyl, C5-C 1 0 heteroaryl,
• R 10 is selected from Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, and
• R u is selected from hydrogen, Ci-C 4 alkyl, C 2 -C4 alkenyl, C 2 -C 4 alkynyl,
• R a is selected from hydrogen, Cj-C 4 alkyl, C 2 -C 4 alkenyl, and C 2 -C 4 alkynyl;
• R b and R c are independently selected from hydrogen, hydroxy, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, and C2-C 4 alkynyl;
• R d and R e are independently selected from: hydrogen, Ci-C 4 alkyl, and a group wherein R d and R e , together with the nitrogen atom to which they are attached, form
• Q is selected from >CH 2 , oxygen, sulfur and
• R f is hydrogen or Ci -C 4 alkyl; n is independently at each occurrence 0, 1, 2, 3 or 4; and x is independently 1 or 2; with the provisos that:
• ring B is phenylene
• R 5 is C 6 -Ci 2 aryl substituted with 0 to 3 R 9 groups
• R 6 is hydrogen.
• R 1 , R 2 , R 3 , and R 4 are hydrogen.
• R 1 and R 2 are independently selected from hydrogen, -O(CR a 2 ) n R 8 , -(CR ⁇ ) n NO 2 , and a group wherein R 1 and R 2 together form a methylenedioxy or an ethylenedioxy group.
• R 7 is selected from hydrogen and methyl.
• ring B is phenylene
• R 5 is C5-C1 0 heteroaryl substituted with 0 to 3 R 9 groups
• R 6 is hydrogen.
• R 1 , R 2 , R 3 , and R 4 are hydrogen.
• R 1 and R are independently selected from hydrogen, -O(CR a 2 ) n R 8 , -(CR ⁇ ) n NO 2 , and a group wherein R 1 and R 2 together form a methylenedioxy or an ethylenedioxy group.
• R 7 is selected from hydrogen and methyl.
• novel compounds are represented by Formula (II):
• R 5 is Cg-Ci 2 aryl substituted with 0 to 3 R 9 groups
• R 6 is hydrogen and R 7 is selected from hydrogen and methyl.
• R 1 , R 2 . R 3 , and R 4 are hydrogen. hi other preferred embodiments, R 2 and R 3 together form a methylenedioxy or an ethylenedioxy group.
• R 1 is hydrogen or -O(CR a 2 ) n
• R 8 and R 2 , R 3 and R 4 are hydrogen .
• R 2 is hydrogen, -O(CR a 2 ) n R 8 or -(CR a 2 ) n NO 2 and R 1 , R 3 and R 4 are hydrogen.
• R 3 is hydrogen or -O(CR a 2 ) n R 8 and R 1 , R 2 and R 4 are hydrogen.
• R 5 is Cs-C 1O heteroaryl substituted with 0 to 3 R 9 groups
• R 6 is hydrogen and R 7 is selected from hydrogen and methyl
• R 1 , R 2 , R 3 , and R 4 are hydrogen.
• R 2 and R 3 together form a methylenedioxy or an ethylenedioxy group
• R 1 is hydrogen or -O(CR a 2)nR S and R 2 , R 3 and R 4 are hydrogen .
• R 2 is hydrogen, -O(CR a 2 )nR 8 or -(CR a 2 ) n NO 2 and R 1 , R 3 and R 4 are hydrogen.
• R 3 is hydrogen or -O(CR a 2 ) n R 8 and R 1 , R 2 and R 4 are hydrogen.
• R 5 is benzofuranyl substituted with 0 to 3 R 9 groups
• R 6 is hydrogen
• R 7 is selected from hydrogen and methyl.
• the present invention provides a pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier. In other preferred embodiments, the present invention provides a pharmaceutical composition comprising a compound of Formula (II) and a pharmaceutically acceptable carrier. In other preferred embodiments, the present invention provides a pharmaceutical composition comprising a compound from Table I and a pharmaceutically acceptable carrier. In other preferred embodiments, the present invention provides a pharmaceutical composition comprising a compound from Table ⁇ and a pharmaceutically acceptable carrier.
• the present invention provides a method of inhibiting a kinase selected from VEGFR2, CDK5 and MLKl, comprising contacting said VEGFR2,
• CDK5 and MLKl with a compound of Formula (I):
• ring B together with the carbon atoms to which it is attached, is a phenylene ring, wherein 1 or 2 carbon atoms of the phenylene ring are optionally replaced by nitrogen atoms;
• ring F is:
• R 1 and R 2 are independently selected from:
• R 2 and R 3 together form a methylenedioxy or an ethylenedioxy group
• R 5 is selected from C 6 -Ci 2 aryl substituted with 0 to 3 R 9 groups, C 3 -C 7 cycloalkyl substituted with 0 to 3 R 9 groups, C5-C10 heterocyclyl substituted with 0 to 3 R 9 groups, and C 5 -C 10 heteroaryl substituted with 0 to 3 R 9 groups;
• R 6 is selected from hydrogen, — CH 2 N(R d )(R e ), and the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
• R 7 is selected from hydrogen, C 1 -Ce alkyl substituted with 0 to 3 R 10 groups, C 2 -C 6 alkenyl substituted with 0 to 3 R 10 groups, C 2 -C 6 alkynyl substituted with 0 to 3 R 10 groups, C 6 -Ci 2 aryl substituted with 0 to 3 R 10 groups,
• R 8 is selected from hydrogen, Cj -C 4 alkyl, C2-C 4 alkenyl, C 2 -C 4 alkynyl, C 6 -C 12 aryl, C 3 -C 7 cycloalkyl, C 5 -C 1 O heterocyclyl, and C 5 -Ci 0 heteroaryl;
• R 9 is selected from:
• R 10 is selected from CrC 6 alkyl, C2-C 6 alkenyl, C 2 -C O alkynyl, halogen, and
• R 11 is selected from hydrogen, Ci -C 4 alkyl, C 2 -C 4 alkenyl, C2-C4 alkynyl, Cg-C 12 aryl, C 3 -C 7 cycloalkyl, C 5 -C 10 heterocyclyl, and C 5 -C 1 0 heteroaryl;
• R a is selected from hydrogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, and C 2 -C 4 alkynyl;
• R b and R c are independently selected from hydrogen, hydroxy, C 1 -C 4 alkyl, C2-C4 alkenyl, and C 2 -C 4 alkynyl;
• R d and R e are independently selected from: (a) hydrogen, C 1 -C 4 alkyl, and
• Q is selected from >CH 2 , oxygen, sulfur and
• R f is hydrogen or Ci-C 4 alkyl
• n is independently at each occurrence 0, 1, 2, 3 or 4
• x is independently 1 or 2.
• the present invention provides a method for treating or preventing angiogenic disorders which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of a compound of Formula (I).
• the angiogenic disorder is cancer of solid tumors, endometriosis, diabetic retinopathy, psoriasis, hemangioblastoma, ocular disorders or macular degeneration.
• the present invention provides a method for treating or preventing Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, peripheral neuropathy, injuries of the brain or spinal cord, cancer, restenosis, osteoporosis, inflammation, viral infections, bone or hematopoietic diseases, autoimmune diseases or transplant rejection which comprises administering to a host in need of such treatment or prevention a therapeutic effective amount of a compound of Formula I.
• the present invention provides a method of treating or preventing Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, peripheral neuropathy, injuries of the brain or spinal cord, cancer, restenosis, osteoporosis, inflammation, viral infections, bone or hematopoietic diseases, autoimmune diseases or transplant rejection which comprises administering to a host in need of such treatment or prevention
• Alzheimer's Disease which comprises administering to a host in need of such treatment or prevention a therapeutic effective amount of a compound of Formula (T).
• the present invention provides for the use of a compound of Formula (I) in the manufacture of a medicament for treating or preventing angiogenic disorders selected from cancer of solid tumors, endometriosis, diabetic retinopathy, psoriasis, hemangioblastoma, ocular disorders and macular degeneration.
• the present invention provides for the use of a compound of Formula (I) in the manufacture of a medicament for treating or preventing Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, peripheral neuropathy, injuries of the brain or spinal cord, cancer, restenosis, osteoporosis, inflammation, viral infections, bone or hematopoietic diseases, autoimmune diseases or transplant rejection.
• the present invention provides for the use of a compound of Formula (I) in the manufacture of a medicament for treating or preventing Alzheimer's disease.
• stable compound or “stable structure” is meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent.
• the present invention is directed only to stable compounds.
• substituted is intended to indicate that one or more hydrogen atoms on an indicated group is replaced with a selected group referred to herein as a “substituent”, provided that the substituted atom's valency is not exceeded, and that the substitution results in a stable compound.
• substituents and substitution patterns on the compounds of the present invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.
• alkyl means a straight-chain, or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isoamyl, neopentyl, 1-ethylpropyl, and hexyl.
• cycloalkyl is meant to refer to a monocyclic saturated or partially unsaturated hydrocarbon group having 3 to 7 carbon atoms.
• cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
• alkylene denotes alkyl groups having two points of attachment; i.e., non-terminal alkyl groups.
• alkylene groups include methylene, ethylene, propylene, butylene, pentylene and hexylene.
• alkenyl is intended to include hydrocarbon chains of either a straight or branched configuration having 2 to 6 carbon atoms and one or more unsaturated carbon-carbon double bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, 3-methylbutenyl, hexenyl and the like.
• alkynyl is intended to include hydrocarbon chains of either a straight or branched configuration having 2 to 6 carbon atoms and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl, 3-methylbutynyl, hexynyl and the like.
• aryl is intended to include an aromatic ring having 6 to 12 carbon atoms.
• aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl, or acenaphthyl.
• fused ring systems including, for example, ring systems in which an aromatic ring is fused to a cycloalkyl ring.
• phenylene denotes a phenyl group having two points of attachment; i.e., a non-terminal phenyl group.
• heterocyclyl or "C 5 -C 1O heterocyclyl”, as used herein, refers to a 5-10 membered monocyclic or bicyclic non-aromatic ring, which may be saturated or partially unsaturated, and which contains, in addition to carbon atoms, at least one heteroatom selected from oxygen, nitrogen, sulfur, selenium, and phosphorus.
• bonds connecting the endocyclic atoms of a heterocyclyl group may be part of a fused aromatic moiety, so long as the heterocyclyl group is not aromatic.
• heterocyclyl groups include, but are not limited to, 2-pyrrolidinyl, 3-pyrrolidinyl, piperdinyl, 2- tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl.
• heteroaryl or "C 5 -C 10 heteroaryl”, as used herein, refers to an aromatic ring system having 5 to 10 ring atoms and which contains, in addition to carbon atoms, at least one heteroatom selected from oxygen, nitrogen or sulfur.
• Non-limiting examples are pyrryl, furanyl, pyridyl, 1,2,4-thiadiazolyl, thiophenyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzothiophenyl, benzofuranyl, pyrazolyl, indolyl, purinyl, carbazolyl, benzk ⁇ idazolyl, isoxazolyl, thiazolyl, indazolyl and quinazolyl.
• halogen as used herein is intended to include chloro, fluoro, bromo and iodo.
• oxy as used as a suffix herein denotes attachment through an oxygen atom.
• amino acid denotes a molecule containing both an amino group and a carboxyl group.
• amino acids include ⁇ -amino, ⁇ - amino, ⁇ -amino acids.
• ⁇ -amino acids are carboxylic acids of general formula HOOC-CH(NH 2 )-(side chain).
• Side chains of amino acids include naturally occurring and non-naturally occurring moieties.
• Non-naturally occurring (i.e., unnatural) amino acid side chains are moieties that are used in place of naturally occurring amino acid side chains in, for example, amino acid analogs.
• Functional groups present on the compounds of Formula I or intermediate compounds may also contain protecting groups.
• Preferred protecting groups include the benzyloxycarbonyl (Cbz; Z) group and the tert-butyloxycarbonyl (Boc) group.
• Other preferred protecting groups may be found in Greene, T. W. and Wuts, P.G.M., Protective Groups in Organic Synthesis 2d. Ed., Wiley & Sons, 1991, a common text in the field, the disclosure of which is incorporated herein by reference.
• effect when used to modify the terms "function” and “survival” means a positive or negative alteration or change.
• An effect which is positive may be referred to herein as an “enhancement” or “enhancing”, and an effect which is negative may be referred to herein as “inhibition” or “inhibiting.”
• inhibitor and “inhibition” mean that a specified response of a designated material (e.g., enzymatic activity) is comparatively decreased in the presence of a compound of the present invention.
• cancer and “cancerous” refer to any malignant proliferation of cells in a mammal.
• examples include prostate, benign prostate hyperplasia, ovarian, breast, brain, lung, pancreatic, colorectal, gastric, stomach, solid tumors, head and neck, neuroblastoma, renal cell carcinoma, lymphoma, leukemia, other recognized malignancies of the hematopoietic systems, and other recognized cancers.
• neuronal cell of neuronal lineage
• neuronal cell include, but are not limited to, a heterogeneous population of neuronal types having singular or multiple transmitters and/or singular or multiple functions; preferably, these are cholinergic and sensory neurons.
• cholinergic neuron means neurons of the Central Nervous System (CNS) and Peripheral Nervous System (PNS) whose neurotransmitter is acetylcholine; exemplary are basal forebrain, striatal, and spinal cord neurons.
• PNS Peripheral Nervous System
• sensor neuron includes neurons responsive to environmental cues (e.g., temperature, movement) from, e.g., skin, muscle and joints; exemplary is a neuron from the dorsal root ganglion.
• a "trophic factor-responsive cell” is a cell which includes a receptor to which a trophic factor can specifically bind; examples include neurons (e.g., cholinergic and sensory neurons) and non-neuronal cells (e.g., monocytes and neoplastic cells).
• a “therapeutically effective amount” refers to an amount of a compound of the present invention effective to prevent or treat the symptoms of a particular disorder. Such disorders include, but are not limited to, those pathological and neurological disorders associated with the aberrant activity of the receptors described herein, wherein the treatment or prevention comprises inhibiting, inducing, or enhancing the activity thereof by contacting the receptor with a compound of Formula I.
• the term "pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
• pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
• pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
• the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
• such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
• inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
• organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic,
• the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
• such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
• nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
• the compounds of the present invention may be prepared in a number of ways well known to those skilled in the art.
• the compounds can be synthesized, for example, by the methods described below, or variations thereon as appreciated by the skilled artisan. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale.
• the compounds of the present invention may contain one or more asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms.
• optically active or racemic forms all chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
• optically active forms mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate generation of target chiral centers.
• functional groups present on the compounds of Formula I may contain protecting groups during the course of synthesis.
• the amino acid side chain substituents of the compounds of Formula I can be substituted with protecting groups such as benzyloxycarbonyl or t-butoxycarbonyl groups.
• protecting groups are known per se as chemical functional groups that can be selectively appended to and removed from functionalities, such as hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention.
• Preferred protecting groups include the benzyloxycarbonyl (Cbz; Z) group and the tert-butyloxycarbonyl (Boc) group.
• Other preferred protecting groups according to the invention may be found in Greene, T.W. and Wuts, P.G.M., Protective Groups in Organic Synthesis 2d. Ed., Wiley & Sons, 1991.
• Compounds 1 may be alkylated by first treatment with a base such as lithium diisopropylamide (LDA), and then reacted with an aldehyde or acid chloride to give the corresponding alcohol. (2) or ketone (3). Conversion of 2 to 3 may be carried out by using an appropriate oxidizing condition, for example Dess-Martin periodinane (J. Am. Chem. Soc. 1991, 113, 7177.) or Swern conditions (DMSO/TFAA). Reaction of 3 with various hydrazines may produce compounds 4.
• Example 4q may be obtained by hydro genation of 4o using an appropriate catalyst, such as 10% palladium on carbon or 20% palladium hydroxide. Reaction of 3 with substituted hydrazines (R-NHNH 2 ) provides a route to N-substituted pyridazinones.
• Indole compounds 11-p may be prepared as outlined in Scheme 2.
• Aldehyde compounds 6 may be prepared by formylation of indoles 5 with phosphorus oxychloride in dimethyl formamide (DMF) (J. Chem. Soc. 1958, 3493). Benzenesulfonyl protection of indole 6 to 7 may be carried out by treatment with benzenesulfonyl chloride in the presence of a base (NaH or NaOH). The aldehyde 7 may be oxidized to the corresponding acid under appropriate oxidizing conditions such as with sodium chlorite ⁇ Acta Chem. Scand. 1973, 27, 888), then sequentially treated with trimethylsilyl diazometha ⁇ e (TMSCHN2) to give methyl ester preparations 1 1-p. la-k may be synthesized from commercially available indole-3-carboxylic acid esters by reaction with benzenesulfonyl chloride in the presence of a base (e.g. sodium hydride or sodium hydroxide).
• a base e.
• Alkylation of indole-3-carboxylate esters with alkyl halides and a base produces 8. Conversion of 8 to 9 or 10 may be achieved as described above for 2 and 3. 9 may be oxidized to 10 under the conditions described for 3. 10 may be converted to compounds 11 under the same conditions as described for Examples 4a-p.
• Compound 13 may be obtained from indole-2-carboxylate esters 12 by treatment with acid chlorides in the presence of an appropriate Lewis acid (e.g. tin tetrachloride). 13 may be converted to compounds 14 using the conditions as described for 4 above by treatment with hydrazine or hydrazine derivatives.
• an appropriate Lewis acid e.g. tin tetrachloride
• Aza compounds may be prepared using the general methods outlined in Scheme 1- 4.
• compounds of general structure 18 may be prepared as outlined in Scheme 5 using conditions described for Scheme 1.
• Aza derivative 15 (Comptes Rendus des Seances de 1'Academie des Sciences, Serie C: Sciences Chimiques, 1967, 265, 1271; J. Heterocyclic Chem., 1968, 5, 461; J. Chem. Soc, Perkin Trans. 1, 1976, 13, 1361; Tetrahedron Lett. 2004, 45, 8087.; J. Chern. Soc. 1960, 131; Chem & Industry 1975, 5, 215. Diss. Abstr. Int.
• X 1 , X 2 , X 3 and X 4 are selected from carbon and nitrogen, may be first treated with a base such as lithium diisopropylamide (LDA), and then with an aldehyde or acid chloride to give corresponding alcohols (16) or ketones (17). Treatment with hydrazine could provide 18.
• a base such as lithium diisopropylamide (LDA)
• LDA lithium diisopropylamide
• hydrazine could provide 18.
• Examples 4b-4p and 4r were prepared using the procedure for compound 4a.
• Example 4o 68 mg, 0.167 mmol
• 10% Pd/C (20 mg) in THF (10 mL) was hydrogenated at 50 psi for 24 h on a Parr apparatus.
• the reaction mixture was filtered through a pad of Celite, which was washed with EtOAc.
• the filtrate was concentrated and dried to give 51 mg (96%) of Example 4q.
• Example 4r 200 mg, 0.69 mmole
• CH 2 Cl 2 5 mL
• N BBr 3 4.0 mL
• Example 4t 120 mg, 0.30 mmol
• 10% Pd/C (12 mg) in 18 mL DMF and 2 mL MeOH was hydrogenated under H 2 at 45 psi for 6 h.
• Example 4d To a stirred solution of Example 4d (50 mg, 0.191 mmol) in acetic acid (10 mL) was added nitric acid (25 ⁇ L, 0.392 mmol). The reaction was heated at reflux for 17 h. Additional of nitric acid (400 ⁇ L) was added to the reaction and continued to reflux for 3 h. The precipitate was collected, washed with water, diethyl ether, and dried under vacuum at 50 0 C to give 48 mg (82%) of Example 4v.
• Example 14c and compound 14d was the same as described for the synthesis of compound 4a.
• the compounds of the present invention are useful, inter alia, as therapeutic agents. Particularly, the compounds are useful for kinase inhibition.
• the compounds of the present invention have been shown to inhibit, for example, one or more of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK), and cyclin-dependent kinase (CDK).
• VEGFR vascular endothelial growth factor receptor
• MLK mixed lineage kinase
• CDK cyclin-dependent kinase
• the properties of the compounds of the present invention are beneficial in therapeutic settings.
• the activities of the fused [d] pyridazin-7-ones of the present invention toward certain enzymes can be exploited to combat the deleterious consequences of these enzymes.
• inhibition of the Vascular Endothelial Growth Factor Receptor (VEGFR) implies utility in, for example, angiogenic disorders, such as cancer of solid tumors, endometriosis, diabetic retinopathy, psoriasis, hemangioblastoma, as well as other ocular diseases and cancers.
• Inhibition of mixed lineage kinase (MLK) implies utility in, for example, Alzheimer's disease; motor neuron disorders (e.g.
• amyotrophic lateral sclerosis Parkinson's disease; cerebrovascular disorders (e.g., stroke, ischaemia); Huntington's disease; AIDS dementia; epilepsy; multiple sclerosis; peripheral neuropathies (e.g., those affecting DRG neurons in chemotherapy-associated peripheral neuropathy) including diabetic neuropathy; disorders induced by excitatory amino acids; and disorders associated with concussive or penetrating injuries of the brain or spinal cord.
• Inhibition of cyclin- dependent kinase (CDK) implies utility in, for example, hyperproliferative diseases and cancer; and Alzheimer's disease.
• fused [d] pyridazin-7-ones may be exploited in other settings, such as research.
• the compounds can be used in the development of in vitro models of neuronal cell survival, function, identification, or for the screening of other synthetic compounds which have activities similar to that of fused [d] pyridazin-7-ones.
• the compounds provided by this invention are useful as standard or reference compounds for use in tests or assays for determining the activity of an agent in a pharmaceutical research program.
• the compounds can also be utilized to investigate, define and determine molecular targets associated with functional responses. For example, by radiolabelling a fused [d] pyridazin-7-one compound associated with a specific cellular function (e.g., mitogenesis), the target entity to which the derivative binds can be identified, isolated, and purified for characterization.
• a fused [d] pyridazin-7-one compound associated with a specific cellular function e.g., mitogenesis
• compounds may be used in the development of assays and models for further enhancement of the understanding of the roles that inhibition of serine/threonine or tyrosine protein kinases play in the mechanistic aspects of the associated disorders and diseases.
• the compounds of the present invention are useful as diagnostic reagents in diagnostic assays, such as the assays described herein.
• the inhibition of enzymatic activity by the compounds of the present invention can be determined using, for example, the following assays: 1. ' Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) kinase inhibition assay; 2. Mixed Lineage Kinase 1 (MLKl) inhibition assay; and 3. Cyclin-Dependent Kinase 5 (CDK5) inhibition assay.
• VEGFR2 Vascular Endothelial Growth Factor Receptor 2
• MLKl Mixed Lineage Kinase 1
• CDK5 inhibition assay Cyclin-Dependent Kinase 5
• IC 50 S were conducted in 96-well Costar high binding plates (Corning Costar #3922, Corning, NY). Briefly, each 96-well plate was coated with 100 ⁇ L/well of 10 ⁇ g/mL recombinant substrate, glutathione S-transferase-phospho lipase C- ⁇ fusion protein (GST-PLC ⁇ Lot # 3P5.1A), in Tris-buffered saline (TBS).
• GST-PLC ⁇ Lot # 3P5.1A glutathione S-transferase-phospho lipase C- ⁇ fusion protein
• Enzyme (30 ng/mL VEGFR2 Lot # V2g-2.1A) was added and the reaction was allowed to proceed at 37°C for 15 minutes.
• Detection of the phosphorylated product was performed by adding 100 ⁇ L/well of Eu-Nl labeled PYlOO antibody (PerkinElmer Life Sciences #AD0160, Boston, MA) diluted 1:5000 in 0.25% BSA in TBS containing 0.05% Tween-20 (TBS-T). Incubation at 37°C then proceeded for 1 hour, followed by addition of 100 ⁇ L enhancement solution (PerkinElmer Life Sciences #1244-105, Boston, MA). The plate was gently agitated and after 30 minutes, the fluorescence of the resulting solution was measured using the PerkinElmer En Vision 2100 (or 2102) multilabel plate reader. The results are summarized in Table III.
• the activity assay for MLKl was performed using the 96- well Millipore Multiscreen plate format.
• Each 50- ⁇ L assay mixture contained 50 mM HEPES (pH 7.0), 1 mM EGTA, 10 mM MgCl 2 , 1 mM DTT, 25 mM ⁇ -glycerophosphate, 60 ⁇ M ATP, 1 ⁇ Ci [Y- 32 P]ATP, 0.1% BSA, 500 ⁇ g/mL myelin basic protein (Upstate #13-104), 2% DMSO, various concentrations of test compound, and 1 ⁇ g/mL of baculoviral GST- MLKI KD (Lot 23.1A). Samples were incubated for 15 minutes at 37°C.
• Detection of the phosphorylated product was performed by adding 100 ⁇ L/well of phospho-Rb (Ser-780) antibody (Cell Signaling #9307, Beverly, MA) diluted 1:10,000 in antibody dilution buffer (0.1% BSA in TBS-T). After 1-hour incubation at room temperature, 100 ⁇ L/well of Eu-Nl labelled anti-rabbit antibody diluted 1:50,000 in antibody dilution buffer (PerkinElmer Life Sciences #AD0105, Boston, MA) was added. Incubation at room temperature then proceeded for 1 hour, followed by addition of 100 ⁇ l enhancement solution (PerkinElmer Life Sciences #1244-105, Boston, MA). The plate was gently agitated and after a few minutes, the fluorescence of the resulting solution was measured using the PerkinElmer En Vision 2100 (or 2102) multilabel plate reader. The results are summarized in Table V.
• the compounds of the present invention can be administered by any means that results in the contact of the active agent with the agent's site of action in the body of a mammal.
• the compounds may be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They are preferably administered as the sole active agent in a pharmaceutical composition, but alternatively, they can be used in combination with other active ingredients, e.g., other growth factors which facilitate neuronal survival or axonal regeneration in diseases or disorders.
• the compounds are preferably combined with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
• compositions for example, by admixture with pharmaceutically acceptable nontoxic excipients and carriers.
• Such compositions can be prepared for use in parenteral administration, particularly in the form of liquid solutions or suspensions; or oral administration, particularly in the form of tablets or capsules; or intranasally, particularly in the form of powders, nasal drops, or aerosols; or dermally, via, for example, trans-dermal patches.
• compositions can be conveniently administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington 's Pharmaceutical Sciences (Mack Pub. Co., Easton, PA, 1980).
• Formulations for parenteral administration may contain as common excipients sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils and vegetable origin, hydrogenated naphthalenes and the like.
• biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene- polyoxypropylene copolymers may be useful excipients to control the release of the active compounds.
• parenteral delivery systems for these active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
• Formulations for inhalation administration contain as excipients, for example, lactose, or may be aqueous solutions containing, for example, ⁇ olyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
• Formulations for parenteral administration may also include glycocholate for buccal administration, a salicylate for rectal administration, or citric acid for vaginal administration.
• Formulations for trans-dermal patches are preferably lipophilic emulsions.
• Compounds of Formula I and pharmaceutically acceptable salts thereof can be administered orally or non-orally, e.g., as an ointment or an injection.
• concentrations of the compounds of this invention in a therapeutic composition can vary. The concentration will depend upon factors such as the total dosage of the drug to be administered, the chemical characteristics (e.g., hydrophobicity) of the compounds employed, the route of administration, the age, body weight and symptoms of a patient, etc..
• the compounds of this invention may be provided in an aqueous physiological buffer solution containing about 0.1 to 10% w/v compound for parenteral administration.
• Typical dose ranges are from about 1 mg to about l ⁇ g/kg of body weight per day; a preferred dose range is from about 0.01 mg/kg to 100 mg/kg of body weight per day, and preferably about 0.1 to 20 mg/kg once to four times per day.
• a preferred dosage of drug to be administered is likely to depend on variables such as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, and formulation of the compound excipient, and its route of administration.
• compositions in accordance with the present invention can be prepared by uniformly mixing an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, as an active ingredient, with a pharmaceutically acceptable carrier.
• the carrier may take a wide range of forms according to the forms of composition suitable for administration. It is desired that such pharmaceutical compositions are prepared in a unit dose form suitable for oral or non-oral administration.
• the forms for non-oral administration include ointment and injection.
• Tablets can be prepared using excipients such as lactose, glucose, sucrose, mannitol and methyl cellulose, disintegrating agents such as starch, sodium alginate, calcium carboxymethyl cellulose and crystalline cellulose, lubricants such as magnesium stearate and talc, binders such as gelatin, polyvinyl alcohol, polyvinyl pyrrolidone, hydroxypropyl cellulose and methyl cellulose, surfactants such as sucrose fatty acid ester and sorbitol fatty acid ester, and the like in a conventional manner. It is preferred that each tablet contains 15-300 r ⁇ g of the active ingredient.
• disintegrating agents such as starch, sodium alginate, calcium carboxymethyl cellulose and crystalline cellulose
• lubricants such as magnesium stearate and talc
• binders such as gelatin, polyvinyl alcohol, polyvinyl pyrrolidone, hydroxypropyl cellulose and methyl cellulose
• surfactants such as suc
• Granules can be prepared using excipients such as lactose and sucrose, disintegrating agents such as starch, binders such as gelatin, and the like in a conventional manner. Powders can be prepared using excipients such as lactose and mannitol, and the like in a conventional manner.
• Capsules can be prepared using gelatin, water, sucrose, gum arabic, sorbitol, glycerin, crystalline cellulose, magnesium stearate, talc, and the like in a conventional manner. It is preferred that each capsule contains 15-300 mg of the active ingredient.
• Syrup preparations can be prepared using sugars such as sucrose, water, ethanol, and the like in a conventional manner.
• Ointment can be prepared using ointment bases such as vaseline, liquid paraffin, lanolin and macrogol, emulsifiers such as sodium lauryl lactate, benzalkonium chloride, sorbitan mono-fatty acid ester, sodium carboxymethyl cellulose and gum arabic, and the like in a conventional manner.
• ointment bases such as vaseline, liquid paraffin, lanolin and macrogol
• emulsifiers such as sodium lauryl lactate, benzalkonium chloride, sorbitan mono-fatty acid ester, sodium carboxymethyl cellulose and gum arabic, and the like in a conventional manner.
• Injectable preparations can be prepared using solvents such as water, physiological saline, vegetable oils (e.g., olive oil and peanut oil), ethyl oleate and propylene glycol, solubilizing agents such as sodium benzoate, sodium salicylate and urethane, isotonicity agents such as sodium chloride and glucose, preservatives such as phenol, cresol, p- hydroxybenzoic ester and chlorobutanol, antioxidants such as ascorbic acid and sodium pyrosulfite, and the like in a conventional manner.
• solvents such as water, physiological saline, vegetable oils (e.g., olive oil and peanut oil), ethyl oleate and propylene glycol, solubilizing agents such as sodium benzoate, sodium salicylate and urethane, isotonicity agents such as sodium chloride and glucose, preservatives such as phenol, cresol, p- hydroxybenzoic ester and chlorobutanol,

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Immunology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Rheumatology (AREA)
• Diabetes (AREA)
• Heart & Thoracic Surgery (AREA)
• Hematology (AREA)
• Endocrinology (AREA)
• Psychology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Pain & Pain Management (AREA)
• Cardiology (AREA)
• Emergency Medicine (AREA)
• Vascular Medicine (AREA)
• Virology (AREA)
• Urology & Nephrology (AREA)
• Ophthalmology & Optometry (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Transplantation (AREA)
• Obesity (AREA)

Priority Applications (10)

Applications Claiming Priority (4)

Publications (1)

Family

ID=38626544

Family Applications (1)

Country Status (11)

Cited By (5)

Families Citing this family (3)

Citations (1)

Family Cites Families (6)

• 2007
  • 2007-06-21 US US11/820,887 patent/US7732447B2/en not_active Expired - Fee Related
  • 2007-06-22 CN CN2007800297073A patent/CN101501038B/zh not_active Expired - Fee Related
  • 2007-06-22 NZ NZ573693A patent/NZ573693A/en not_active IP Right Cessation
  • 2007-06-22 WO PCT/US2007/014559 patent/WO2007149557A1/en not_active Ceased
  • 2007-06-22 ES ES07796360T patent/ES2393216T3/es active Active
  • 2007-06-22 AU AU2007261305A patent/AU2007261305B2/en not_active Ceased
  • 2007-06-22 MX MX2008016388A patent/MX2008016388A/es active IP Right Grant
  • 2007-06-22 EP EP07796360A patent/EP2035429B1/en not_active Not-in-force
  • 2007-06-22 JP JP2009516579A patent/JP2010504277A/ja not_active Ceased
  • 2007-06-22 CA CA002656034A patent/CA2656034A1/en not_active Abandoned
• 2008
  • 2008-12-17 IL IL196014A patent/IL196014A0/en unknown

Patent Citations (1)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events